1. "GSK Faculty"
Formats
  1. Journal Article (13834)
  2. Meeting Abstract (7076)
  3. Review (514)
  4. Book Section (342)
  5. Editorial (307)
  6. Conference Paper (162)
  7. Research Letter (96)
  8. Miscellaneous (45)
  9. Correspondence (38)
  10. Guidelines (32)
  11. Book Whole (22)
Groups
  1. GSK Faculty (22468)
  2. Sloan Kettering Institute Faculty (11482)
  3. Department of Medicine (10529)
  4. Tow Center for Developmental Oncology (TCDO) (6948)
  5. Sloan Kettering Institute Postdocs (6210)
  6. Solid Tumor Oncology Division (5880)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Steven Larson (957)
  3. Jedd Wolchok (905)
  4. Cristina Antonescu (895)
  5. Kenneth Offit (788)
  6. David Solit (779)

More People

Years
  1. 2025 (296)
  2. 2024 (868)
  3. 2023 (1016)
  4. 2022 (1152)
  5. 2021 (1088)
  6. 2020 (1257)

More Years

Publications
  1. Blood (1470)
  2. Journal of Clinical Oncology (1279)
  3. Cancer Research (1104)
  4. Clinical Cancer Research (527)
  5. Modern Pathology (494)
  6. Journal of Nuclear Medicine (474)

More Publications

Publishers
  1. Nature Publishing Group (2594)
  2. American Association for Cancer Research (2194)
  3. Elsevier Inc. (1937)
  4. American Society of Hematology (1553)
  5. Cell Press (1421)
  6. American Society of Clinical Oncology (1379)

More Publishers

Results (22468)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development
    Meeting Abstract

    Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD) detection by ctDNA in relation to radiographic disease progression in patients with stage I-III non-small cell lung cancer (NSCLC) treated with definitive radiation therapy
    Meeting Abstract

    Lebow, E. S.; Murciano-Goroff, Y. R.; Jee, J.; Kalashnikova, E.; Feeney, J.; Sethi, H.; Aleshin, A.; Kris, M. G.; Chaft, J. E.; Rudin, C. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Biomarkers of response to neoadjuvant atezolizumab with gemcitabine and cisplatin in muscle-invasive bladder cancer
    Meeting Abstract

    Lattanzi, M.; Solovyov, A.; Lihm, J.; Quinlan, C.; Whiting, K.; Li, H.; Al-Ahmadie, H. A.; Teo, M. Y.; Aggen, D. H.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor-positive breast cancer
    Meeting Abstract

    Lacouture, M. E.; Pan, A.; Dranitsaris, G.; Harris, U.; Chandarlapaty, S.; Dang, C. T.; Gajria, D.; Gordon, A.; Iyengar, N. M.; Robson, M. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Oral minoxidil for the treatment of late alopecia in cancer survivors
    Meeting Abstract

    Kuo, A. M. S.; Reingold, R. E.; Ketosugbo, K.; Pan, A.; Dusza, S. W.; Kraehenbuehl, L.; Gajria, D.; Lake, D. E.; Bromberg, J.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Subclonal somatic copy number alterations emerge and dominate in recurrent osteosarcoma
    Meeting Abstract

    Kinnaman, M. D.; Zaccaria, S.; Makohon-Moore, A.; Gundem, G.; Ossa, J. E. A.; Bouvier, N.; Dela Cruz, F. S.; Hameed, M.; Bender, J. L. G.; Tap, W. D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A robust, trial-agnostic gene signature for response to tyrosine kinase inhibition in ccRRCC
    Meeting Abstract

    Khaleel, S. S.; Liu, M.; Kuo, F.; Kotecha, R.; Lee, C. H.; Voss, M. H.; Motzer, R. J.; Hakimi, A. A.; Reznik, E.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134)
    Meeting Abstract

    Jensen, R. E.; Zheng, Y.; Atkins, M. B.; Chmielowski, B.; Tarhini, A. A.; Truong, T. G.; Davar, D.; O'Rourke, M. A.; Curti, B. D.; Brell, J. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A breast cancer (BC) risk model incorporating Tyrer-Cuzick version 8 (TCv8) and a polygenic risk score (PRS) for diverse ancestries
    Meeting Abstract

    Hughes, E.; Probst, B.; Pederson, H. J.; Simmons, T.; Morris, B.; Domchek, S. M.; Eng, C.; Gary, M.; Gordon, O.; Klemp, J. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067
    Meeting Abstract

    Hodi, F. S.; Chiarion-Sileni, V.; Lewis, K. D.; Grob, J. J.; Rutkowski, P.; Lao, C. D.; Cowey, C. L.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save